Primary action sites: area postrema and nucleus of the solitary tract (NTS) in the brainstem
Factors (such as GABA and urocortin 3) released by the -cells stimulate somatostatin secretion, thereby providing a mechanism for feedback control of insulin and glucagon secretion during hyperglycaemia
Here are the key details: Start date: July 1, 2026 End date: December 31, 2027 (unless extended by Congress) Eligible medications: FDA-approved anti-obesity medications, including Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) Patient cost: Flat $50 per month copay Deductible: Waived - the Part D deductible does not apply to medications obtained through this program Prior authorization: Required by most Part D plans, but criteria are standardized under the program The bridge structure is important to understand
And long lines
Legitimate access to retatrutide is limited to participation in an appropriate clinical trial with defined eligibility criteria, informed consent, study oversight, and monitoring by the trial team
Most formulations can be kept at room temperaturebetween 59F and 86Ffor up to 28 days after the first injection